Hodgkin lymphoma: Current status and clinical trial recommendations

Catherine S. Diefenbach, Joseph M. Connors, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl, Richard F. Little, Lawrence Baizer, Andrew M. Evens, Richard T. Hoppe, Kara M. Kelly, Daniel O. Persky, Anas Younes, Lale Kostakaglu, Nancy L. Bartlett

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials. Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN.

Original languageEnglish
Article numberdjw249
JournalJournal of the National Cancer Institute
Volume109
Issue number4
DOIs
StatePublished - 2017

Fingerprint Dive into the research topics of 'Hodgkin lymphoma: Current status and clinical trial recommendations'. Together they form a unique fingerprint.

  • Cite this

    Diefenbach, C. S., Connors, J. M., Friedberg, J. W., Leonard, J. P., Kahl, B. S., Little, R. F., Baizer, L., Evens, A. M., Hoppe, R. T., Kelly, K. M., Persky, D. O., Younes, A., Kostakaglu, L., & Bartlett, N. L. (2017). Hodgkin lymphoma: Current status and clinical trial recommendations. Journal of the National Cancer Institute, 109(4), [djw249]. https://doi.org/10.1093/jnci/djw249